Ignite Creation Date:
2024-05-06 @ 4:26 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04989322
Status:
RECRUITING
Last Update Posted:
2021-12-08
First Post:
2021-07-26
Brief Title:
Pembrolizumab Lenvatinib and Chemotherapy After TKIs in NSCLC
Sponsor:
Dr Joanne CHIU
Organization:
The University of Hong Kong
Study Overview
Official Title:
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer NSCLC Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
Status:
RECRUITING
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR ALK or ROS1 genetic aberration refractory to standard targeted therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3475-C50 | OTHER | MSD | None |